China · Delayed Price · Currency is CNY NOVAST Laboratories Company Description
NOVAST Laboratories, Limited develops, manufactures, and sells prescription drug formulations.
The company produces controlled-release formulations, including extended-release and sustained-release tablets and capsules, as well as low-dose drug formulations.
Its products include Metoprolol Succinate Extended-Release Tablets, Nifedipine Extended-Release Tablets, Diltiazem Hydrochloride Extended-Release Capsules, Metformin Hydrochloride Sustained-Release Tablets, Levonorgestrel Tablets, Memantine Hydrochloride Extended-Release Capsules, Quetiapine Fumarate Sustained-Release Tablets, and Tolterodine tablets for urinary frequency and urgency.
The company also develops a digestive-system extended-release tablet designated DG-062. Additionally, the company provides formulation contract research organization (CRO) services, including prescription process development and regulatory filing and clinical support services for pharmaceutical companies and research institutions, as well as outsourced CRO and contract manufacturing organization (CMO) services for innovative drugs.
NOVAST Laboratories, Limited was incorporated in 2005 and is based in Nantong, China.
| Country | China |
| Founded | 2005 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 709 |
| CEO | Guohua Zhang |
Contact Details
Address: No. 1, Guangxing Road Nantong, 226010 China | |
| Phone | 86 513 8598 6623 |
| Website | novast.cn |
Stock Details
| Ticker Symbol | 301569 |
| Exchange | Shenzhen Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE1000080W6 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Guohua Zhang | Chief Executive Officer |
| Shuqiang Zhang | Chief Financial Officer |